Stockscreener 앱 받기
7.67
2.54%
-0.20
시간 외 거래:
7.60
-0.07
-0.91%
전일 마감가:
$7.87
열려 있는:
$7.96
하루 거래량:
310.02K
Relative Volume:
0.83
시가총액:
$372.67M
수익:
$251.00K
순이익/손실:
$-83.87M
주가수익비율:
-2.2356
EPS:
-3.4309
순현금흐름:
$-79.34M
1주 성능:
-10.29%
1개월 성능:
-25.68%
6개월 성능:
+114.25%
1년 성능:
+293.33%
1일 변동 폭
$7.60
$8.18
1주일 범위
$7.60
$9.045
52주 변동 폭
$1.47
$14.53
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
명칭
Artiva Biotherapeutics Inc
전화
(858) 267-4467
주소
5505 MOREHOUSE DRIVE, SAN DIEGO
Compare ARTV vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARTV
Artiva Biotherapeutics Inc
|
7.67 | 382.39M | 251.00K | -83.87M | -79.34M | -3.4309 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-11 | 재개 | H.C. Wainwright | Buy |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-13 | 개시 | Jefferies | Buy |
| 2024-08-13 | 개시 | Needham | Buy |
| 2024-08-13 | 개시 | TD Cowen | Buy |
| 2024-08-13 | 개시 | Wedbush | Outperform |
모두보기
Artiva Biotherapeutics Inc 주식(ARTV)의 최신 뉴스
Cantor Fitzgerald reiterates Artiva Biotherapeutics stock rating By Investing.com - Investing.com Australia
ARTV Stock Price, Quote & Chart | ARTIVA BIOTHERAPEUTICS INC (NASDAQ:ARTV) - ChartMill
Have Insiders Sold Artiva Biotherapeutics Shares Recently? - simplywall.st
Artiva Biotherapeutics CMO Subhashis Banerjee sells $63,386 in stock By Investing.com - Investing.com Nigeria
As Griffith retires, Dittrich returns to Amgen, takes CFO role - biocentury.com
Artiva Biotherapeutics COO Jennifer Bush sells $79,178 in stock By Investing.com - Investing.com Nigeria
Artiva names Diego Miralles as president and head of R&D - The Pharma Letter
Artiva Biotherapeutics CMO Subhashis Banerjee sells $63,386 in stock - Investing.com India
Artiva Biotherapeutics COO Jennifer Bush sells $79,178 in stock - Investing.com India
Artiva Biotherapeutics CEO Fred Aslan sells $244,252 of stock By Investing.com - Investing.com Nigeria
Artiva Biotherapeutics CEO Fred Aslan sells $244,252 of stock - Investing.com India
Artiva Biotherapeutics SVP Heather Raymon sells $27,879 in stock By Investing.com - Investing.com Australia
Artiva Biotherapeutics officer Christopher Horan sells $63,072 in stock - Investing.com India
Artiva Biotherapeutics SVP Heather Raymon sells $27,879 in stock - Investing.com India
Artiva Biotherapeutics officer Christopher Horan sells $63,072 in stock By Investing.com - Investing.com Australia
Artiva Biotherapeutics, Inc. to present five abstracts on AlloNK at EULAR 2026 across multiple diseases - Traders Union
Artiva Biotherapeutics announces executive changes and new appointments By Investing.com - Investing.com Nigeria
Artiva to present AlloNK therapy data at EULAR congress - Investing.com India
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases - Yahoo Finance
Artiva Biotherapeutics appoints Diego Miralles as president, R&D head By Investing.com - Investing.com Nigeria
Artiva Biotherapeutics, Inc. Appoints New Principal Financial Officer and President in May 2026 - Minichart
Artiva Biotherapeutics announces executive changes and new appointments - Investing.com
Artiva Biotherapeutics Inc Thad Huston to separate as CFO effective May 22, 2026 - marketscreener.com
Artiva Biotherapeutics Inc Thad Huston To Separate As CFO Effective May 22, 2026 - TradingView
Artiva Biotherapeutics Names Diego Miralles, M.D., as Pres and Head of Research and Development >ARTV - Moomoo
Artiva Biotherapeutics Announces Major Executive Leadership Transitions - TipRanks
Artiva Biotherapeutics appoints Diego Miralles as president, R&D head - Investing.com
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, ... - Enidnews.com
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development - Yahoo Finance UK
Artiva Biotherapeutics (ARTV) price target increased by 60.00% to 27.74 - MSN
Major Insider Move Signals Big Confidence in Artiva Biotherapeutics - TipRanks
Ra Capital Management acquires $75m in Artiva Biotherapeutics shares By Investing.com - Investing.com Australia
Ra Capital Management acquires $75m in Artiva Biotherapeutics shares - Investing.com
TradingKey - TradingKey
Needham Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Raises Target Price to $41 - Moomoo
TD Cowen Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating - Moomoo
Business News, Finance News, Stock Market - RTTNews
Cantor Fitzgerald Boosts Artiva Biotherapeutics (NASDAQ:ARTV) Price Target to $40.00 - MarketBeat
H.C. Wainwright raises Artiva Biotherapeutics price target to $35 - Investing.com
H.C. Wainwright raises Artiva Biotherapeutics price target to $35 By Investing.com - Investing.com Canada
Artiva Biotherapeutics stock slides despite positive trial data - MSN
Number of shareholders of Artiva Biotherapeutics, Inc. – NASDAQ:ARTV - TradingView
Artiva Biotherapeutics Announces $300 Million Equity Offering - The Globe and Mail
Artiva Biotherapeutics: Runway To Fund Operations Into 2Q 2027 >ARTV - Moomoo
Artiva Biotherapeutics Announces Underwriting Agreement and Public Offering of Shares and Pre-Funded Warrants - Minichart
Latham Watkins Advises on Artiva Biotherapeutics Offering of Common Stock and Pre Funded Warrants - Latham & Watkins LLP
Artiva reports clinical trial data for rheumatoid arthritis therapy - Investing.com UK
Artiva Biotherapeutics: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA - Seeking Alpha
Artiva Biotherapeutics Inc (ARTV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):